Targeting “Zombie Cells”: A Breakthrough in Reversing Liver Damage

UCLA researchers have identified a specific population of immune cells that accumulate in aging tissues and the livers of individuals with fatty liver disease. These cells, known as senescent macrophages, contribute to chronic inflammation and tissue degradation. The study, published in Nature Aging, reveals that clearing these cells can significantly reduce inflammation and reverse liver damage in animal models, even without changes to diet.

Understanding Cellular Senescence

Cellular senescence is a stress response mechanism where cells cease to divide but do not undergo programmed cell death. Instead, these “zombie cells” persist in tissues, secreting inflammatory signals that disrupt normal cellular function. While macrophages—immune cells responsible for clearing debris and pathogens—were previously thought to be incapable of senescence, the UCLA team has confirmed their role in pathological aging.

The research team, led by Anthony Covarrubias of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, identified a distinct molecular signature for these cells. By tracking two proteins, p21 and TREM2, researchers were able to distinguish genuinely senescent macrophages from those performing their standard immune functions.

The Role of Cholesterol and Metabolism

The study found that while the proportion of senescent macrophages increases naturally with age, diet plays a critical role in their proliferation. Exposure to high levels of LDL cholesterol can trigger the senescence process in healthy macrophages. This finding links metabolic health directly to the accumulation of these dysfunctional immune cells, particularly in the context of fatty liver disease.

According to Ivan Salladay-Perez, a graduate student in the Covarrubias lab, the pathological state arises when the body’s ability to manage cholesterol metabolism is overwhelmed by chronic overnutrition. This suggests that the accumulation of senescent macrophages may be a fundamental mechanism driving metabolic decline across various tissues, including the heart and brain.

Reversing Liver Damage

In experiments involving mice with metabolic liver disease, the researchers utilized a compound known as ABT-263 to selectively induce death in senescent cells. The intervention yielded significant results:

• Liver Health: Treated livers showed a marked reduction in size and a return to healthier physical characteristics compared to the fatty, enlarged livers of untreated subjects.
• Metabolic Impact: The reduction in senescent cells led to a decrease in overall body weight, suggesting that targeting these cells can provide metabolic benefits independent of dietary intervention.

Future Implications for Human Health

The research team confirmed the presence of the p21-TREM2 signature in human genomic datasets, indicating that macrophage senescence is a relevant factor in human chronic liver disease. Given that fatty liver disease affects a substantial portion of the population, these findings offer a potential pathway for new therapeutic strategies.

While the compound used in the study is considered too toxic for human application, the team is now focused on identifying alternative compounds that can safely eliminate senescent macrophages. This work aligns with the geroscience hypothesis, which posits that targeting the fundamental mechanisms of aging could provide treatments for a wide range of age-related conditions, including cancer, atherosclerosis, and neurodegenerative diseases like Alzheimer’s.

Key Takeaways

• New Biological Target: Senescent macrophages have been identified as a key driver of inflammation and liver damage.
• Diagnostic Marker: The p21-TREM2 protein signature allows researchers to accurately identify dysfunctional immune cells.
• Reversible Pathology: Clearing these cells has demonstrated the potential to reverse liver damage in preclinical models.
• Broad Potential: The research suggests that targeting these mechanisms could address multiple age-related diseases beyond liver health.

This study was supported by the National Institutes of Health, the Glenn Foundation for Medical Research, the American Federation for Aging Research, and the UCLA-UCSD Diabetes Research Center.